F.D.A. Panel Rejects Drug for Obesity

Law360, New York (June 14, 2007, 12:00 AM EDT) -- The French drug company Sanofi-aventis announced on Wednesday that a Food and Drug Administration advisory panel has voted unanimously not to recommend approving its new weight loss drug, citing concerns about its effectiveness and safety.

The drug, known as rimonabant and already sold in 37 countries under the brand name Acomplia, was approved by the European Medical Agency in June 2006. Sanofi had intended to market it in the United States as Zimulti.

The drug is indicated for treating obesity, but has not been shown to...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.